VRTX241101P535000
- 0.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Express News | Vertex Pharmaceuticals Inc : Oppenheimer Cuts Target Price to $540 From $550
Earnings Preview: VRTX to Report Financial Results Post-market on November 04
$Vertex Pharmaceuticals(VRTX.US)$ is scheduled to release its financial results post-market on November 04 ET. Earnings PreviewAnalysts estimate $Vertex Pharmaceuticals(VRTX.US)$ to post revenue of
Wells Fargo Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $555
Vertex to Participate in Upcoming November Investor Conferences
CCORF Maintains Vertex Pharmaceuticals(VRTX.US) With Sell Rating, Cuts Target Price to $361
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 5 Years
Scotiabank Initiates Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Announces Target Price $480
Truist Financial Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
Vertex Pharmaceuticals (VRTX) Gets a Buy From Truist Financial
Barclays Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $509
Vertex Pharmaceuticals: Hold Rating Amid Promising Developments and Pending Long-Term Validation
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
Recent 5.4% Pullback Isn't Enough to Hurt Long-term Vertex Pharmaceuticals (NASDAQ:VRTX) Shareholders, They're Still up 159% Over 3 Years
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $515
Piper Sandler Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $535
Piper Sandler Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Editas Reviews Path for Gene Editing Therapy to Save Costs
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today
Looking Into Vertex Pharmaceuticals's Recent Short Interest